Bayer's shares have hit their lowest point in 20 years due to multiple setbacks including a decline in Q4 profits, a 7% share drop following a U.S. court's decision to review the Monsanto case, and a weak Q3 performance. CEO Bill Anderson acknowledges that results haven't been pretty, urging for calm. While pharma chief announced no major acquisitions in near future. U.S hedge fund, however, have bet on falling Bayer shares. Innovation seems to be a potential saving grace for Bayer. The company saw a surge in its stock after winning a legal battle against Roundup cancer claims. The company also has made advances within AI technology. However, its partnership with OneMedNet for AI medical imaging hasn't been enough to fully rescue the declining stock performance. Additionally, a Washington Supreme Court decision to reopen a PCB case pushed Bayer's share further down. The outlook for Bayer's stock remains cautious, despite some upsides like positive results for an MRI contrast agent.
BAYER Stocks News Analytics from Mon, 20 Nov 2023 08:00:00 GMT to Mon, 03 Feb 2025 08:00:00 GMT -
Rating -6
- Innovation 2
- Information 5
- Rumor -8
